LabCorp launches new neutralizing antibody test for COVID-19
(Reuters) - LabCorp launched a new test on Thursday to assess the ability of antibodies in patient plasma to inhibit the novel coronavirus.
Information from the test on the ability of antibodies to fight viruses could be used in the development of COVID-19 vaccines, the company said.
The test, called the neutralizing antibody test, would be available to biopharmaceutical companies, hospitals, blood banks, and other blood plasma screening facilities.
According to the Mayo Clinic, neutralizing antibodies are associated with protective immunity against re-infection for many infectious pathogens.
The test could be used to screen serum collected from recovered COVID-19 patients for preventive and therapeutic use, the company said.
The company released its COVID-19 tests to workplaces last month and also offers laboratory tests and antibody blood tests to determine if a person has ever been infected, as well as kits that people can use to send their own collected nasal swab samples at home .
(Reporting by Manojna Maddipatla in Bengaluru; editing by Aditya Soni)
You should check here to buy the best price guaranteed products.
A perfect wedding out of the ashes
Putin says relations with U.S. at lowest point in years
French Open runner-up Tsitsipas says he learned a lesson
Susan Collins: Bipartisan infrastructure plan proposes user tax for electric vehicle 'free riders'
Commercial space travel gaining foothold in tourism industry
The One Big Question About Trump’s DoJ Spying on Dems